Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
A phase 3 trial of Bicalutamide, Buserelin, Flutamide, Goserelin / leuprolide, Leuprolide and Nilutamide in Prostate cancer, run by NCIC Clinical Trials Group, completed.
Overview
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer is a phase 3 interventional study registered as NCT00003653 by NCIC Clinical Trials Group, with 1386 participants recorded, started 1999-01-05 and reaching its primary completion in 2010-10-04. Interventions recorded: bicalutamide, buserelin, cyproterone acetate, flutamide, goserelin, leuprolide acetate, nilutamide. Conditions recorded: Prostate Cancer.
Linked to the drug Nilutamide because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialHormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer
Shares Nilutamide, Buserelin, Flutamide, Bicalutamide and the tag pipeline.
- TrialProstate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
Shares Buserelin, Flutamide, Bicalutamide, Goserelin / leuprolide (ovarian function suppression) and the tag pipeline.
- TrialRadiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Shares Buserelin, Flutamide, Bicalutamide, Goserelin / leuprolide (ovarian function suppression) and the tag pipeline.
- TrialFlutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer
Shares Flutamide, Goserelin / leuprolide (ovarian function suppression), Leuprolide (leuprorelin) and GnRH agonists, Prostate cancer and the tag pipeline.
- TrialStandard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Shares Nilutamide, Flutamide, Bicalutamide, Goserelin / leuprolide (ovarian function suppression) and the tag pipeline.
- TrialTwo Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
Shares Buserelin, Flutamide, Bicalutamide, Goserelin / leuprolide (ovarian function suppression) and the tag pipeline.
- TrialHormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
Shares Flutamide, Bicalutamide, Prostate cancer and the tag pipeline.
- TrialNeoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
Shares Bicalutamide, Goserelin / leuprolide (ovarian function suppression), Prostate cancer and the tag pipeline.